An Atypical Carcinoid Tumour Secreting 5-Hydroxytryptophan

Sandler, M.; Snow, P.J.D.

doi:10.1016/s0140-6736(58)90616-0

Cited by 122 publications

(22 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…But in the maintenance of cellular levels of 5-HT, it is unlikely that the uptake of 5-HTP is of itself important, since 5-HTP is not present in the culture medium and probably does not exist in blood. Extracellular, endogenous 5-HTP has been described only in patients with atypical carcinoid tumours (Sandler & Snow, 1958;Sandler, Scheuer & Watt, 1961). If 5-HTP was a normal component of blood, 5-HT would have a wider distribution than it has, for many tissues can decarboxylate 5-HTP but only some normally contain 5-HT (Westermann, Balzer & Knell, 1958).…”

Section: Discussionmentioning

confidence: 99%

The uptake of amino acids and the synthesis of amines by neoplastic mast cells in culture

Day¹,

Green²

1962

The Journal of Physiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The uptake of amino acids and the synthesis of amines by neoplastic mast cells in culture

Day¹,

Green²

1962

The Journal of Physiology

View full text Add to dashboard Cite

“…First of all, 5-HTP has been found in considerable amounts in the urine of some patients suffering from carcinoidosis [1038,1140,335] and in one of these patients dietary 14C-tryptophan was shown to have been converted into labelled 5-HTP [1125J.…”

Section: Conversion Of L-tryptophan Into L-5-htp and L-4-htpmentioning

confidence: 99%

Recent Research in the Field of 5-Hydroxytryptamine and Related Indolealkylamines

Erspamer

1961

Fortschritte Der Arzneimittelforschung / Progress in Drug Research / Progrès Des Recherches Pharmaceutiques

View full text Add to dashboard Cite

“…A possible explanation for this difference could be that bronchial NETs produce histamine and 5-hydroxytryptophan, the precursor of 5-hydroxytryptamine (serotonin), unlike small-bowel NETs, which produce serotonin (34,35). It may be hypothesized that CT better visualizes a bone reaction caused by secretion of 5-hydroxytryptophan than that caused by serotonin.…”

Section: Discussionmentioning

confidence: 99%

Tumor Response Assessment to Treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions

et al. 2012

View full text Add to dashboard Cite

We have noted that bone lesions on CT respond differently from soft-tissue lesions to treatment with [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate ( 177 Lu-octreotate). We therefore compared the response of bone lesions with that of soft-tissue lesions to treatment with 177 Luoctreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors (NETs). Methods: Forty-two patients with well-differentiated NETs who had bone metastases that were positive on [ 111 In-DTPA 0 ]octreotide somatostatin receptor scintigraphy (SRS) before treatment, and who had soft-tissue lesions, were studied. All patients had had a minimum of 1 follow-up CT scan. Lesions were scored on CT and bone lesions also on SRS before and after treatment. Tumor markers (chromogranin A and 5-hydroxyindoleacetic acid) before and after treatment were compared. Results: Because bone lesions were not visible on CT before treatment in 11 of 42 patients (26%), bone and softtissue lesions were evaluated in 31 patients. Whereas bone lesions increased in size, soft-tissue lesions decreased in size. The percentage change in bone and soft-tissue lesions was significantly different at all time points up to 12 mo of follow-up (P , 0.001). The intensity or number of bone lesions on SRS decreased after treatment in 19 of 23 patients (83%) in whom SRS after treatment was available. The tumor markers also decreased significantly after treatment. In 1 patient, bone lesions became visible on CT after treatment, mimicking progressive disease with "new" bone lesions, although there was an overall treatment response. Conclusion: In patients with NETs, the apparent increase in size of bone lesions or the appearance of new bone lesions on CT after treatment with 177 Lu-octreotate should be interpreted cautiously, as this finding may be therapy-related rather than indicative of tumor progression.

show abstract

An Atypical Carcinoid Tumour Secreting 5-Hydroxytryptophan

Cited by 122 publications

References 16 publications

The uptake of amino acids and the synthesis of amines by neoplastic mast cells in culture

The uptake of amino acids and the synthesis of amines by neoplastic mast cells in culture

Recent Research in the Field of 5-Hydroxytryptamine and Related Indolealkylamines

Tumor Response Assessment to Treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions

Contact Info

Product

Resources

About

An Atypical Carcinoid Tumour Secreting 5-Hydroxytryptophan

Cited by 122 publications

References 16 publications

The uptake of amino acids and the synthesis of amines by neoplastic mast cells in culture

The uptake of amino acids and the synthesis of amines by neoplastic mast cells in culture

Recent Research in the Field of 5-Hydroxytryptamine and Related Indolealkylamines

Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions

Contact Info

Product

Resources

About

Tumor Response Assessment to Treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions